Blinatumoab公司
CD19
医学
免疫学
淋巴细胞白血病
白血病
癌症研究
抗原
作者
Friederike Braig,Anna Brandt,Mariele Goebeler,Hans‐Peter Tony,Anna-Katharina Kurze,Peter Nollau,Thomas G.P. Bumm,Sebastian Böttcher,Ralf C. Bargou,Mascha Binder
出处
期刊:Blood
[American Society of Hematology]
日期:2017-01-05
卷期号:129 (1): 100-104
被引量:184
标识
DOI:10.1182/blood-2016-05-718395
摘要
Key Points CD19− relapses are a major challenge in about 10% to 20% of patients treated with blinatumomab. Molecular workup of 1 case revealed a disrupted CD19 membrane export as the basis for blinatumomab resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI